Modality
Vaccine
MOA
BCL-2i
Target
MET
Pathway
RNA Splicing
Parkinson'sObesity
Development Pipeline
Preclinical
~Feb 2019
→ ~May 2020
Phase 1
Aug 2020
→ Apr 2030
Phase 1Current
NCT03813810
2,266 pts·Obesity
2020-08→2029-11·Completed
NCT07471166
1,716 pts·Parkinson's
2024-11→2030-04·Terminated
3,982 total pts2 indications
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (2)
2029-11-133.6y awayInterim· Obesity
2030-04-154.0y awayInterim· Parkinson's
Trial Timeline
Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2
P1
Complet…
P1
Termina…
Catalysts
Interim
2029-11-13 · 3.6y away
Obesity
Interim
2030-04-15 · 4.0y away
Parkinson's
CompletedTerminated|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT03813810 | Phase 1 | Obesity | Completed | 2266 | DAS28 |
| NCT07471166 | Phase 1 | Parkinson's | Terminated | 1716 | 6MWD |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| PFE-5501 | Pfizer | Phase 1 | BTK | |
| RHH-3592 | Roche | Phase 1/2 | GIP-R | |
| Geliderotide | Novartis | NDA/BLA | IL-17A | |
| SNY-5783 | Sanofi | Phase 1/2 | MET | |
| Tezecilimab | Takeda | NDA/BLA | Tau | |
| Rimaosocimab | Amgen | Preclinical | FXIa | |
| Sotosacituzumab | Vertex Pharma | Phase 1 | MET | |
| Capifutibatinib | Incyte | Phase 3 | PCSK9 | |
| NBI-408 | Neurocrine | Phase 2/3 | KRASG12D | |
| HAL-996 | Halozyme | Phase 1/2 | BCL-2 |